Citations

Mayo Clinic

Clear

6266 citation(s) found for "Ip, Andrew".

Distinctive MRI findings in pallidopontonigral degeneration (PPND)
Frank, Andrew , Jack, Clifford R. , Wszołek, Zbigniew K. , Boeve, Bradley F. , Jack, Clifford R

Neurology | February 19, 2007 | Volume: 68 | Issue: 8 | Pages: 620-621

10.1212/01.wnl.0000254614.39759.3d | PMID 17310038 Get It

Surgical and Interventional Visceral Revascularization for the Treatment of Chronic Mesenteric Ischemia—When to Prefer Which?
Oldenburg, W. Andrew, Paz‐Fumagalli, Ricardo , McKinney, J. Mark , Hakaim, Albert G., Biebl, Matthias

World Journal of Surgery | February 15, 2007 | Volume: 31 | Issue: 3 | Pages: 562-568

10.1007/s00268-006-0434-5 | PMID 17334867 Get It

AbstractBackgroundThe purpose of the present study was to compare surgical and endovascular revascularization for chronic mesenteric ischemia (CMI).MethodsForty‐nine patients underwent surgical (SG) or endovascular (EG) treatment. Relief of symptoms was considered the primary endpoint; patency, morbidity, and mortality were secondary endpoints. For statistical analysis, significance was assumed if P values ≤ 0.05.ResultsTwenty‐six patients (53%) underwent surgical revascularization; 23 patients (47%), endovascular repair. Mean follow‐up was 25 ± 21 months (SG) versus 10 ± 10 (EG) months (P = 0.07). Except for body mass indices (SG 18.9 ± 2.7 versus EG 23.6 ± 4.8; P = 0.001), preoperative data were comparable. Freedom from symptoms was 100% (SG) versus 90% (EG) after intervention (P = 0.194), and 89% (SG) versus 75% (EG) at the end of follow‐up. Reocclusion or re‐stenosis occurred in 8% (SG) versus 25% (EG) (log‐rank test: P = 0.003), and mesenteric ischemia developed in 0% (SG) versus 9% (EG) (P = 0.04). Reintervention for CMI was required in 0% (SG) versus 13% (EG) (P = 0.01). Surgical patients experienced more early complications (42% versus EG 4%; P = 0.02) and longer hospital stays (11.6 ± 10.9 days versus EG 1.3 ± 0.5 days; P < 0.001). Overall mortality at the end of follow‐up was 31% (SG) versus 4% (EG) (log‐rank test: P = 0.08), including all patients with combined open mesenteric and aortic reconstruction (P = 0.001).ConclusionsSurgical treatment has superior long‐term patency and requires fewer reinterventions, but it is also more invasive with greater morbidity and mortality compared to endovascular treatment. Endovascular techniques may be preferable in patients with significant co‐morbidities, concomitant aortic disease, or indeterminate symptoms.
Lack of aggregation of ischemic stroke subtypes within affected sibling pairs
Wiklund, Per-Gunnar, Brown, W. Mark , Brott, Thomas G. , Brown, Robert D., Nilsson-Ardnor, Sofie, Hardy, John , Kissela, Brett , Singleton, Andrew , Holmberg, Dan , Rich, Stephen S. , Stegmayr, Bernd Georg , Meschia, James F. , Rich, Stephen S , Hardy, John

Neurology | February 5, 2007 | Volume: 68 | Issue: 6 | Pages: 427-431

10.1212/01.wnl.0000252955.17126.6a | PMID 17283317 Get It

Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer
Axtell, Allison E., Lee, Margaret H., Bristow, Robert E. , Dowdy, Sean C. , Cliby, William A. , Raman, Steven, Weaver, John P. , Gabbay, Mojan, Ngo, Michael , Lentz, Scott E. , Cass, Ilana , Li, Andrew J., Holschneider, Christine H., Karlan, Beth Y.

Journal of Clinical Oncology | February 2, 2007 | Volume: 25 | Issue: 4 | Pages: 384-389

10.1200/jco.2006.07.7800 | PMID 17264334 Get It

Purpose Identify features on preoperative computed tomography (CT) scans to predict suboptimal primary cytoreduction in patients treated for advanced ovarian cancer in institution A. Reciprocally cross validate the predictors identified with those from two previously published cohorts from institutions B and C. Patients and Methods Preoperative CT scans from patients with stage III/IV epithelial ovarian cancer who underwent primary cytoreduction in institution A between 1999 and 2005 were retrospectively reviewed by radiologists blinded to surgical outcome. Fourteen criteria were assessed. Crossvalidation was performed by applying predictive model A to the patients from cohorts B and C, and reciprocally applying predictive models B and C to cohort A. Results Sixty-five patients from institution A were included. The rate of optimal cytoreduction (≤ 1 cm residual disease) was 78%. Diaphragm disease and large bowel mesentery implants were the only CT predictors of suboptimal cytoreduction on univariate (P < .02) and multivariate analysis (P < .02). In combination (model A), these predictors had a sensitivity of 79%, a specificity of 75%, and an accuracy of 77% for suboptimal cytoreduction. When model A was applied to cohorts B and C, accuracy rates dropped to 34% and 64%, respectively. Reciprocally, models B and C had accuracy rates of 93% and 79% in their original cohorts, which fell to 74% and 48% in cohort A. Conclusion The high accuracy rates of CT predictors of suboptimal cytoreduction in the original cohorts could not be confirmed in the cross validation. Preoperative CT predictors should be used with caution when deciding between surgical cytoreduction and neoadjuvant chemotherapy.
Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , Andrei, Adin‐Cristian , King, Talmadge E. , Raghu, Ganesh , Colby, Thomas V. , Wells, Athol U. , Bassily, Nadir, Brown, Kevin K. , Bois, Roland du, Flint, Andrew , Gay, Steven E., Gross, Barry H., Kazerooni, Ella A. , Knapp, Robert H., Louvar, Edmund, Lynch, David A. , Quick, John S., Vyskocil, J , Wadenstorer, Frazer A., Wilt, Jeffrey, Toews, Galen B., Murray, Susan , Nicholson, Andrew G. , Thannickal, Victor J. , Travis, William D. , Martínez, Fernando J.

American Journal of Respiratory and Critical Care Medicine | January 25, 2007 | Volume: 175 | Issue: 10 | Pages: 1054-1060

10.1164/rccm.200606-833oc | PMID 17255566 Get It

Abstract Rationale Treatment and prognoses of diffuse parenchymal lung diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis among observers is difficult. Objectives Evaluate diagnostic agreement between academic and community-based physicians for patients with DPLDs, and determine if an interactive approach between clinicians, radiologists, and pathologists improved diagnostic agreement in community and academic centers. Methods Retrospective review of 39 patients with DPLD. A total of 19 participants reviewed cases at 2 community locations and 1 academic location. Information from the history, physical examination, pulmonary function testing, high-resolution computed tomography, and surgical lung biopsy was collected. Data were presented in the same sequential fashion to three groups of physicians on separate days. Measurements and Main Results Each observer's diagnosis was coded into one of eight categories. A κ statistic allowing for multiple raters was used to assess agreement in diagnosis. Interactions between clinicians, radiologists, and pathologists improved interobserver agreement at both community and academic sites; however, final agreement was better within academic centers (κ = 0.55–0.71) than within community centers (κ = 0.32–0.44). Clinically significant disagreement was present between academic and community-based physicians (κ = 0.11–0.56). Community physicians were more likely to assign a final diagnosis of idiopathic pulmonary fibrosis compared with academic physicians. Conclusions Significant disagreement exists in the diagnosis of DPLD between physicians based in communities compared with those in academic centers. Wherever possible, patients should be referred to centers with expertise in diffuse parenchymal lung disorders to help clarify the diagnosis and provide suggestions regarding treatment options.
Perioperative Cardiac Arrests in Children between 1988 and 2005 at a Tertiary Referral Center
Flick, Randall P., Harrison, Tracy E. , Gleich, Stephen J. , Schroeder, Darrell R. , Hanson, Andrew C. , Buenvenida, Shonie L., Warner, David O., Šprung, Juraj , Schroeder, Darrell

Anesthesiology | January 22, 2007 | Volume: 106 | Issue: 2 | Pages: 226-237

10.1097/00000542-200702000-00009 | PMID 17264715 Get It

Background The objective of this study was to determine the incidence and outcome of perioperative cardiac arrest (CA) in children younger than 18 yr undergoing anesthesia for noncardiac and cardiac procedures at a tertiary care center. Methods After institutional review board approval (Mayo Clinic, Rochester, Minnesota), all patients younger than 18 yr who had perioperative CA between November 1, 1988, and June 30, 2005, were identified. Perioperative CA was defined as a need for cardiopulmonary resuscitation or death during anesthesia care. A cardiac procedure was defined as a surgical procedure involving the heart or great vessels requiring an incision. Results A total of 92,881 anesthetics were administered during the study period, of which 4,242 (5%) were for the repair of congenital heart malformations. The incidence of perioperative CA during noncardiac procedures was 2.9 per 10,000, and the incidence during cardiac procedures was 127 per 10,000. The incidence of perioperative CA attributable to anesthesia was 0.65 per 10,000 anesthetics, representing 7.5% of the 80 perioperative CAs. Both CA incidence and mortality were highest among neonates (0-30 days of life) undergoing cardiac procedures (incidence: 435 per 10,000; mortality: 389 per 10,000). Regardless of procedure type, most patients who experienced perioperative CA (88%) had congenital heart disease. Conclusion The majority of perioperative CAs were caused by factors not attributed to anesthesia, in distinction to some recent reports. The incidence of perioperative CA is many-fold higher in children undergoing cardiac procedures, suggesting that definition of case mix is necessary to accurately interpret epidemiologic studies of perioperative CA in children.
Prognosis of Fibrotic Interstitial Pneumonia
Park, Joo Hun , Kim, Dong Soon, Park, I-Nae , Jang, Se Jin , Kitaichi, Masanori, Colby, Thomas V. , Nicholson, Andrew G.

American Journal of Respiratory and Critical Care Medicine | January 11, 2007 | Volume: 175 | Issue: 7 | Pages: 705-711

10.1164/rccm.200607-912oc | PMID 17218621 Get It

Abstract Background To investigate whether the better prognosis of interstitial pneumonias associated with collagen vascular disease (CVD) compared with idiopathic interstitial pneumonia (IIP) is due to higher frequency of the nonspecific interstitial pneumonia (NSIP) pattern in CVD, we compared the outcomes of patients from these two groups with the same histopathologic pattern. Subjects The clinical features and survival of 362 patients (269 with IIP and 93 with CVD) diagnosed using surgical lung biopsy were analyzed. Results The mean survival of the CVD group (131.0 mo) was longer than that of the IIP group (80.5 mo) (p &lt; 0.0001). The patients with usual interstitial pneumonia pattern among the CVD group (n = 36) was younger, female, and predominantly nonsmoking compared with the IIP group (n = 203). Although baseline lung functions were not significantly different, the CVD group survived longer (mean, 177.0 mo) than the IIP group (mean, 66.9 ± 6.5 mo; p = 0.001). By multivariate analysis, younger age, better pulmonary function, and the presence of a CVD were independent prognostic factors. In NSIP pattern, no significant differences in survival, clinical features, or lung function were found between the two groups. Conclusion Our data suggest that the better prognosis of patients in the CVD group is not solely due to the predominance of the NSIP pattern. The prognosis of patients with the usual interstitial pneumonia pattern in CVD is better than in those with idiopathic pulmonary fibrosis, despite the same pathologic pattern. In contrast, in those with an NSIP pattern, the prognosis is similar in both groups.
The Impact of Ischemia Time During Open Nephron Sparing Surgery on Solitary Kidneys: A Multi-Institutional Study
Thompson, R. Houston, Frank, Igor, Lohse, Christine M. , Saad, Ismail R., Fergany, Amr, Zincke, Horst, Leibovich, Bradley C. , Blute, Michael L., Novick, Andrew C.

Journal of Urology | January 11, 2007 | Volume: 177 | Issue: 2 | Pages: 471-476

10.1016/j.juro.2006.09.036 | PMID 17222613 Get It

Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations
Kavsak, Peter A. , Newman, Alice, Lustig, Viliam, MacRae, Andrew R., Ko, Dennis T. , Tu, Jack V. , Jaffe, Allan S. , Richards, C. Sue , Jaffe, Allan S.

Clinical Chemistry | January 5, 2007 | Volume: 53 | Issue: 2 | Pages: 220-227

10.1373/clinchem.2006.076885 | PMID 17204519 Get It

Abstract Background: Recent data suggest that older men with detectable cardiac troponin I (cTnI) concentrations that remain below the 99th percentile concentration cutoff are at increased risk for subsequent cardiovascular events. We designed this study to extend this observation by examining risk prediction in both men and women presenting to an emergency department with chest discomfort. Methods: We obtained data for all-cause mortality and hospital discharges associated with either acute myocardial infarction (AMI) or congestive heart failure (CHF) for up to 8 years after the initial presentation in 448 patients who originally presented in 1996 with acute coronary syndrome (ACS). We performed retrospective analysis for cTnI (AccuTnI™; Beckman Coulter) in frozen plasma samples based on the patients’ reported time from onset of symptoms. Peak cTnI concentration was used for risk assessment. Results: Patients with cTnI concentrations ≥0.02 μg/L (i.e., limit of detection), including those whose peak values remained below the 99th percentile (0.04 μg/L), were at greater risk for death and AMI/CHF readmissions at 2, 5, and 8 years of follow-up compared with those with peak cTnI &lt;0.02 μg/L. All results were statistically significant (P &lt;0.05) except for death within 2 years among patients with normal but detectable cTnI (0.02 to 0.03 μg/L), relative to the group with values &lt;0.02 μg/L. Kaplan–Meier analyses indicated that both men and women with cTnI ≥0.02 μg/L had worse outcomes (P &lt;0.001). Conclusion: Both men and women who present with possible ACS with detectable cTnI concentrations that remain below the 99th percentile are at a greater risk for future adverse events.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Mulligan, George , Mitsiades, Constantine S. , Bryant, Barbara M. , Roels, Steven , Koenig, Erik , Fergus, Andrew, Huang, Yongsheng , Richardson, Paul G. , Trepicchio, William L. , Broyl, Annemiek, Sonneveld, Pieter , Shaughnessy, John D. , Bergsagel, P. Leif , Schenkein, David P., Esseltine, Dixie‐Lee, Boral, Anthony, Zhan, Fenghuang , Zhan, Fenghuang , Chng, Wee Joo , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Bergsagel, P. Leif , Zhan, Fenghuang , Mulligan, George

Blood | December 21, 2006 | Volume: 109 | Issue: 8 | Pages: 3177-3188

10.1182/blood-2006-09-044974 | PMID 17185464 Get It

Abstract The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor cells, and these samples were used for gene expression profiling using DNA microarrays. Data quality and correlations with trial outcomes were assessed by multiple groups. Gene expression in this dataset was consistent with data published from a single-center study of newly diagnosed multiple myeloma. Response and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data. The survival classifier improved on the risk stratification provided by the International Staging System. Predictive models and biologic correlates of response show some specificity for bortezomib rather than dexamethasone. Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents.